Patents by Inventor Lee Lim
Lee Lim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12559799Abstract: The present invention includes compositions and methods useful for the detection of a mutational change, SNP, translocation, inversion, deletion, change in copy number, or other genetic variation within a sample of cellular genomic DNA or cell-free DNA (cfDNA). In some embodiments, the compositions and methods of the present invention provide an extremely high level of resolution that is particularly useful in detecting copy number variations in a small fraction of the total cfDNA from a biological sample (e.g., blood).Type: GrantFiled: January 27, 2022Date of Patent: February 24, 2026Assignee: Resolution Bioscience, Inc.Inventors: Christopher Raymond, Lee Lim, Jennifer Hernandez
-
Publication number: 20240191293Abstract: The disclosure provides compositions and methods that combine the benefits of different genetic analysis methods by performing simultaneous genetic analysis on a single pool of different libraries that were generated for different approaches, such as a combined library comprising a LPWG library and a target-enriched library.Type: ApplicationFiled: March 30, 2022Publication date: June 13, 2024Inventors: Jiannan Guo, Carolyn Hutcheon, Mark Li, Lee Lim, Ira Pekker, Chen-Hsun Tsai
-
Publication number: 20220325353Abstract: The present invention includes compositions and methods useful for the detection of a mutational change. SNP, translocation, inversion, deletion, change in copy number, or other genetic variation within a sample of cellular genomic DNA or cell-free DNA (cfDNA). In some embodiments, the compositions and methods of the present invention provide an extremely high level of resolution that is particularly useful in detecting copy number variations in a small fraction of the total cfDNA from a biological sample (e.g., blood).Type: ApplicationFiled: January 27, 2022Publication date: October 13, 2022Inventors: Christopher RAYMOND, Lee LIM, Jennifer HERNANDEZ
-
Publication number: 20220267763Abstract: The invention provides a method for efficient DNA library construction and targeted genetic analyses of the libraries.Type: ApplicationFiled: January 28, 2022Publication date: August 25, 2022Inventors: Christopher RAYMOND, Lee LIM
-
Patent number: 11319594Abstract: The present invention includes compositions and methods useful for the detection of a mutational change, SNP, translocation, inversion, deletion, change in copy number, or other genetic variation within a sample of cellular genomic DNA or cell-free DNA (cfDNA). In some embodiments, the compositions and methods of the present invention provide an extremely high level of resolution that is particularly useful in detecting copy number variations in a small fraction of the total cfDNA from a biological sample (e.g., blood).Type: GrantFiled: August 24, 2017Date of Patent: May 3, 2022Assignee: Resolution Bioscience, Inc.Inventors: Christopher Raymond, Lee Lim, Jennifer Hernandez
-
Patent number: 10584335Abstract: The instant disclosure features single-stranded RNA molecules comprising one or more internal, non-nucleotide spacers. A non-nucleotide spacer covalently links nucleotide portions of the molecule. The single-stranded RNA molecules function as guide or antisense strands that are capable of inhibiting gene expression via an RNA interference mechanism and, thus, represent single-stranded RNAi agents. The single-stranded RNAi molecules can be used in methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.Type: GrantFiled: November 10, 2017Date of Patent: March 10, 2020Assignee: SIRNA THERAPEUTICS, INC.Inventors: Lee Lim, Guillaume Chorn, Aarron T. Willingham, Lihong Zhao
-
Patent number: 10526602Abstract: This invention relates generally to segmented oligonucleotides capable of modulating gene expression. Specifically, the instant invention relates to segmented microRNA (miRNA) oligonucleotides, including segmented miRNA precursors and segmented pre-microRNAs. The invention also relates to compositions comprising such segmented oligonucleotides, as well as to methods of making and using such oligonucleotides for diagnosis and treatment of diseases associated or causally linked to aberrant levels or activities of gene expression, including aberrant levels of coding and/or non-coding RNA.Type: GrantFiled: July 12, 2017Date of Patent: January 7, 2020Assignee: SIRNA THERAPEUTICS, INC.Inventors: Guillaume Chorn, Lee Lim, Lihong Zhao
-
Publication number: 20180163272Abstract: The present invention includes compositions and methods useful for the detection of a mutational change, SNP, translocation, inversion, deletion, change in copy number, or other genetic variation within a sample of cellular genomic DNA or cell-free DNA (cfDNA). In some embodiments, the compositions and methods of the present invention provide an extremely high level of resolution that is particularly useful in detecting copy number variations in a small fraction of the total cfDNA from a biological sample (e.g., blood).Type: ApplicationFiled: August 24, 2017Publication date: June 14, 2018Inventors: Christopher Raymond, Lee Lim, Jennifer Hernandez
-
Publication number: 20180112216Abstract: This invention relates generally to segmented oligonucleotides capable of modulating gene expression. Specifically, the instant invention relates to segmented microRNA (miRNA) oligonucleotides, including segmented miRNA precursors and segmented pre-microRNAs. The invention also relates to compositions comprising such segmented oligonucleotides, as well as to methods of making and using such oligonucleotides for diagnosis and treatment of diseases associated or causally linked to aberrant levels or activities of gene expression, including aberrant levels of coding and/or non-coding RNA.Type: ApplicationFiled: July 12, 2017Publication date: April 26, 2018Inventors: Guillaume Chorn, Lee Lim, Lihong Zhao
-
Publication number: 20180080024Abstract: The instant disclosure features single-stranded RNA molecules comprising one or more internal, non-nucleotide spacers. A non-nucleotide spacer covalently links nucleotide portions of the molecule. The single-stranded RNA molecules function as guide or antisense strands that are capable of inhibiting gene expression via an RNA interference mechanism and, thus, represent single-stranded RNAi agents. The single-stranded RNAi molecules can be used in methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.Type: ApplicationFiled: November 10, 2017Publication date: March 22, 2018Applicant: SIRNA THERAPEUTICS, INC.Inventors: Lee Lim, Guillaume Chorn, Aarron T. Willingham, Lihong Zhao
-
Patent number: 9845466Abstract: Single-stranded RNA molecules comprise one or more internal, non-nucleotide spacers, covalently linked with nucleotide portions of the molecule are provided. The single-stranded RNA molecules function as guide or antisense strands that are capable of inhibiting gene expression via an RNA interference mechanism, and thus represent single-stranded RNAi agents. The single-stranded RNAi molecules can be used in methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.Type: GrantFiled: December 14, 2015Date of Patent: December 19, 2017Assignee: SIRNA THERAPEUTICS, INC.Inventors: Lee Lim, Guillaume Chorn, Aarron T. Willingham, Lihong Zhao
-
Patent number: 9732342Abstract: This invention relates generally to segmented oligonucleotides capable of modulating gene expression. Specifically, the instant invention relates to segmented microRNA (miRNA) oligonucleotides, including segmented miRNA precursors and segmented pre-microRNAs. The invention also relates to compositions comprising such segmented oligonucleotides, as well as to methods of making and using such oligonucleotides for diagnosis and treatment of diseases associated or causally linked to aberrant levels or activities of gene expression, including aberrant levels of coding and/or non-coding RNA.Type: GrantFiled: June 23, 2015Date of Patent: August 15, 2017Assignee: SIRNA THERAPEUTICS, INC.Inventors: Guillaume Chorn, Lee Lim, Lihong Zhao
-
Publication number: 20160222381Abstract: Single-stranded RNA molecules comprise one or more internal, non-nucleotide spacers, covalently linked with nucleotide portions of the molecule are provided. The single-stranded RNA molecules function as guide or antisense strands that are capable of inhibiting gene expression via an RNA interference mechanism, and thus represent single-stranded RNAi agents. The single-stranded RNAi molecules can be used in methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.Type: ApplicationFiled: December 14, 2015Publication date: August 4, 2016Applicant: SIRNA THERAPEUTICS, INC.Inventors: Lee Lim, Guillaume Chorn, Aarron T. Willingham, Lihong Zhao
-
Patent number: 9243246Abstract: Single-stranded RNA molecules comprise one or more internal, non-nucleotide spacers, covalently linked with nucleotide portions of the molecule are provided. The single-stranded RNA molecules function as guide or antisense strands that are capable of inhibiting gene expression via an RNA interference mechanism, and thus represent single-stranded RNAi agents. The single-stranded RNAi molecules can be used in methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.Type: GrantFiled: August 19, 2011Date of Patent: January 26, 2016Assignee: Sirna Therapeutics, Inc.Inventors: Lee Lim, Guillaume Chorn, Aarron Willingham, Lihong Zhao
-
Publication number: 20150376613Abstract: This invention relates generally to segmented oligonucleotides capable of modulating gene expression. Specifically, the instant invention relates to segmented microRNA (miRNA) oligonucleotides, including segmented miRNA precursors and segmented pre-microRNAs. The invention also relates to compositions comprising such segmented oligonucleotides, as well as to methods of making and using such oligonucleotides for diagnosis and treatment of diseases associated or causally linked to aberrant levels or activities of gene expression, including aberrant levels of coding and/or non-coding RNA.Type: ApplicationFiled: June 23, 2015Publication date: December 31, 2015Applicant: SIRNA THERAPEUTICS, INC.Inventors: Guillaume Chorn, Lee Lim, Lihong Zhao
-
Patent number: 9200275Abstract: In one aspect, a method is provided of inhibiting proliferation of a mammalian cell comprising introducing into said cell an effective amount of at least one at least one small interfering RNA agent (iRNA), wherein said iRNA comprises a nucleotide sequence of at least 15 nucleotides, wherein the nucleotide sequence comprises a seed region consisting of nucleotide positions 1 to 12, wherein position 1 represents the 5? end of the iRNA nucleotide sequence and wherein said seed region comprises a nucleotide sequence of at least six contiguous nucleotides that is complementary to six contiguous nucleotides within positions 1 to 12 of a nucleotide sequence, wherein position 1 represents the 5?end of the nucleotide sequence, wherein the nucleotide sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.Type: GrantFiled: June 14, 2007Date of Patent: December 1, 2015Assignee: Merck Sharp & Dohme Corp.Inventors: Peter S. Linsley, Janell Schelter, Julja Burchard, Lee Lim, Miho Kibukawa
-
Patent number: 9096850Abstract: This invention relates generally to segmented oligonucleotides capable of modulating gene expression. Specifically, the instant invention relates to segmented microRNA (miRNA) oligonucleotides, including segmented miRNA precursors and segmented pre-microRNAs. The invention also relates to compositions comprising such segmented oligonucleotides, as well as to methods of making and using such oligonucleotides for diagnosis and treatment of diseases associated or causally linked to aberrant levels or activities of gene expression, including aberrant levels of coding and/or non-coding RNA.Type: GrantFiled: August 24, 2010Date of Patent: August 4, 2015Assignee: Sirna Therapeutics, Inc.Inventors: Guillaume Chorn, Lee Lim, Lihong Zhao
-
Publication number: 20130225652Abstract: This invention relates generally to segmented oligonucleotides capable of modulating gene expression. Specifically, the instant invention relates to segmented microRNA (miRNA) oligonucleotides, including segmented miRNA precursors and segmented pre-microRNAs. The invention also relates to compositions comprising such segmented oligonucleotides, as well as to methods of making and using such oligonucleotides for diagnosis and treatment of diseases associated or causally linked to aberrant levels or activities of gene expression, including aberrant levels of coding and/or non-coding RNA.Type: ApplicationFiled: August 24, 2010Publication date: August 29, 2013Inventors: Guillaume Chorn, Lee Lim, Lihong Zhao
-
Publication number: 20130171242Abstract: Single-stranded RNA molecules comprise one or more internal, non-nucleotide spacers, covalently linked with nucleotide portions of the molecule are provided. The single-stranded RNA molecules function as guide or antisense strands that are capable of inhibiting gene expression via an RNA interference mechanism, and thus represent single-stranded RNAi agents. The single-stranded RNAi molecules can be used in methods for a variety of therapeutic, diagnostic, target validation, genomic discovery, genetic engineering, and pharmacogenomic applications.Type: ApplicationFiled: August 19, 2011Publication date: July 4, 2013Inventors: Lee Lim, Guillaume Chorn, Aarron Willingham, Lihong Zhao
-
Publication number: 20110111976Abstract: One aspect of the invention generally relates to use of tissue enriched miRNAs as biomarker to estimate tissue damage in a fluid sample. In a second aspect, methods are provided for monitoring a subject who is exposed or might have been exposed to an agent that has a risk of causing tissue injury. In a third aspect, methods are provided for identifying an agent as having a risk of causing tissue injury to a vertebrate subject. In a fourth aspect, kits are provided for practicing the methods of above-listed aspects. The contents of this ABSTRACT are not intended to in anyway limit the scope of the inventions claimed herein.Type: ApplicationFiled: April 24, 2009Publication date: May 12, 2011Applicant: Merck Sharp & Dohme Corp.Inventors: Thomas L. Fare, Philip W. Garrett-Engele, Warren E. Glaab, Jason M. Johnson, Omar F. Laterza, Lee Lim, Steve W. Ludmerer, David B. Olsen, Joseph F. Sina, Frank D. Sistare